Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 5Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 4OTHER 2OTHER_GOV 1

Study Type

Interventional 7

Sponsor

Cancer Type

Head & Neck 1Classical hematology 1

Conditions

Pain 27Neoplasms 20Cancer Pain 10Colonic Neoplasms 7Breakthrough Pain 7Agnosia 7Breast Neoplasms 5Rectal Neoplasms 4Prostatic Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 4Chronic Pain 4Urinary Bladder Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Pain, Postoperative 3Lymphoma, Follicular 3Breakthrough Cancer Pain 3Waldenstrom Macroglobulinemia 2Uterine Cervical Neoplasms 2Thrombocythemia, Essential 2Sezary Syndrome 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Pleural Effusion, Malignant 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Myeloproliferative Disorders 2Mycosis Fungoides 2

Interventions

Fentanyl 7Morphine 2Urinary Catheterization 1Ultracet 1Patient Positioning 1Passive Cutaneous Anaphylaxis 1Methadone 1Infusions, Intravenous 1Gastrostomy 1Administration, Sublingual 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Breakthrough Pain × Fentanyl × Clear all
NCT00263575 2024-06-18

Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

Kyowa Kirin Co., Ltd.

Phase 3 Completed
139 enrolled 7 charts

Neoplasms, Pain, Breakthrough Pain

NCT05037539 2022-08-31

Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain

Department of Medical Services Ministry of Public Health of Thailand

Phase 1/2 Completed
20 enrolled

Breakthrough Pain

NCT03809455 2020-04-22

FARADI

UNICANCER

Phase 2 Withdrawn

Breakthrough Pain

NCT02869321 2019-05-13

ANTALGIP

Central Hospital, Nancy, France

Phase 4 Completed
20 enrolled
Head & Neck

Head and Neck Neoplasms, Breakthrough Pain

NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236145 2013-01-29

Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed

Breakthrough Pain

NCT00842829 2012-10-01

Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 4 Terminated
330 enrolled 32 charts

Cancer Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡